EGFR and colorectal cancer: While the use of immunotherapies such as anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have found reasonable ground against EGFR positive colorectal cancer patients, the absence of effective targeted immunotherapies against EGFR positive patients harboring a mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) gene have yet to be addressed.